For better monitoring of tumor molecular changes, liquid biopsy is emerging as a more convenient and potentially lower-cost alternative to tissue biopsy. Liquid biopsy detects genetic aberrations in circulating tumor cells and deoxyribonucleic acid from apoptotic and necrotic tumor cells.
Winston Patrick Kuo
Winston Patrick Kuo (winston.kuo@ cloudhealth99.com) is the chief technology officer and head of business development with CloudHealth Genomics, Ltd., Shanghai, China. He was formerly president of Predicine Holdings Ltd., an international precision-medicine organization committed to developing innovative diagnostics, therapeutics, and big data in cancer and other serious diseases; he was chief operating officer with IES Diagnostics. Prior to industry, Dr. Kuo was an assistant professor in the Department of Developmental Biology at the Harvard School of Dental Medicine, and he was director and founder of the Harvard Clinical and Translational Science–Laboratory for Innovative Translational Technologies at the Harvard Medical School to provide the university’s biomedical research community with early access to disruptive and enabling leading-edge translational technologies.